"The National Institutes of Health is looking for volunteers to take part in a study to compare the long-term benefits and risks of four widely used diabetes drugs in combination with metformin, the most common first-line medication for treatin"...
Novolin R (recombinant dna origin) is indicated for subcutaneous administration for the treatment of patients with diabetes mellitus, for the control of hyperglycemia. Treatment with Novolin R (recombinant dna origin) is as an adjunct to diet and exercise for lowering blood glucose in patients with Type 1 diabetes or in patients with Type 2 diabetes for whom oral antidiabetic therapy is inadequate.
Novolin R (recombinant dna origin) may be administered intravenously under proper medical supervision in a clinical setting for glycemic control. (See DOSAGE AND ADMINISTRATION and Recommended Storage.)
DOSAGE AND ADMINISTRATION
Novolin R (recombinant dna origin) , when used alone subcutaneously, is usually given three or more times daily before meals. The dosage and timing of Novolin R (recombinant dna origin) should be individualized and determined, based on the physician's advice, in accordance with the needs of the patient. Novolin R (recombinant dna origin) may also be used in combination with oral antidiabetic agents or longer-acting insulin products to suit the needs of the individual patients. The injection of Novolin R (recombinant dna origin) should be followed by a meal within approximately 30 minutes of administration The average range of total daily insulin requirement for maintenance therapy in insulin-treated patients lies between 0.5 and 1.0 IU/kg. However, in pre-pubertal children it usually varies from 0.7 to 1.0 IU/kg but can be much lower during the period of partial remission. In severe insulin resistance, e.g. during puberty or due to obesity, the daily insulin requirement may be substantially higher. Initial dosages for Type 2 diabetes patients are often lower, e.g. 0.2 to 0.4 IU/kg/day
Novolin R (recombinant dna origin) should be administered by subcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm. Subcutaneous injection into the abdominal wall ensures a faster absorption than from other injection sites. Injection into a lifted skin fold minimizes the risk of intramuscular injection. Injection sites should be rotated within the same region. As with all insulins, the duration of action will vary according to the dose, injection site, blood flow, temperature, and level of physical activity.
Intramuscular and intravenous administrations of Novolin R (recombinant dna origin) are possible under medical supervision with close monitoring of blood glucose and potassium levels to avoid hypoglycemia and hypokalemia. For intravenous use, Novolin R (recombinant dna origin) should be used at concentrations from 0.05 U/mL to 1.0 U/mL in infusion systems with the infusion fluids 0.9% sodium chloride, 5% dextrose, or 10% dextrose with 40 mmol/l potassium chloride using polypropylene infusion bags.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Never use Novolin R (recombinant dna origin) if it has become viscous (thickened) or cloudy; use it only if it is clear and colorless. Novolin R (recombinant dna origin) should not be used after the printed expiration date.
Novolin R vials, Novolin® R (recombinant dna origin) PenFill® cartridges, and Novolin® R (recombinant dna origin) InnoLet® prefilled insulin syringes should be stored in a cold (36°-46°F [2°-8°C]) place, preferably in a refrigerator, but not in the freezer. Do not freeze. Keep Novolin R (recombinant dna origin) vials, Novolin R (recombinant dna origin) PenFill cartridges and Novolin R (recombinant dna origin) InnoLet in their cartons so that they will stay clean and protected from light. They should not be exposed to heat or sunlight. A Novolin R (recombinant dna origin) vial in use can be kept unrefrigerated as long as it is kept as cool as possible and away from heat or sunlight. A Novolin R (recombinant dna origin) PenFill cartridge and Novolin R (recombinant dna origin) InnoLet in use should not be refrigerated but should be kept as cool as possible (below 86°F [30°C]) and away from direct heat and light. Unrefrigerated Novolin R (recombinant dna origin) PenFill cartridges and Novolin R (recombinant dna origin) InnoLet must be discarded 28 days after the first use, even if they still contain Novolin R (recombinant dna origin) insulin.
Infusion bags prepared as indicated under DOSAGE AND ADMINISTRATION are stable at room temperature for 24 hours. A certain amount of insulin will be initially adsorbed to the material of the infusion bag.
Never use insulin after the expiration date which is printed on the label and carton.
Novolin R (recombinant dna origin) , Regular, Human Insulin Injection (rDNA origin) USP, 100 units/mL, is supplied as follows:
10 mL vial....................................NDC 0169-1833-11
3 mL PenFill cartridges*................NDC 0169-3473-18
3 mL Novolin R (recombinant dna origin) InnoLet.................NDC 0169-2313-21
*Novolin R (recombinant dna origin) PenFill 3 mL cartridges are designed for use with Novo Nordisk 3 mL PenFill cartridge compatible insulin delivery devices, the NovoPen®3 PenMate® and with NovoFine® disposable needles
For information contact: Novo Nordisk Inc., Princeton, NJ 08540. 1-800-727-6500. www.novonordisk-us.com. Manufactured by: Novo Nordisk A/S DK-2880 Bagsvaerd, Denmark. Date of issue: October 21, 2005
Last reviewed on RxList: 4/5/2012
This monograph has been modified to include the generic and brand name in many instances.
Additional Novolin R Information
Report Problems to the Food and Drug Administration
Find tips and advances in treatment.